RE: Strong H1 results today7 Dec 2022 08:54
SDI are still on a very decent value multiple, especially compared to its sector comparator JDG which trades on a much higher rating.
Here's Progressive's new note with 9.5p EPS forecast this year:
Https://progressive-research.com/wp-content/uploads/data-sync/research/SDI%2020221207.pdf?utm_source=sendgrid.com&utm_medium=email&utm_campaign=website
Extracts:
"Another strong set of results
"SDI Group has announced strong H1 results to 31 October, with the full year
expected to be in line with market expectations. Total revenue increased by
28.3% to £31.7m and adjusted operating profit by 19% to £6.9m. Despite
increased global economic uncertainty, SDI’s niche businesses, operating in
diverse end markets, have driven overall organic revenue growth of 3.8%.
Safelab Systems and Scientific Vacuum Systems (SVS) acquired over FY 2022
and LTE Scientific Limited (LTE) in the first half of FY23, contributed to the
strong sales growth, alongside the well-flagged, one-off Covid-19 related
contracts within Atik Cameras. Management notes that post-Covid
fluctuations in demand haven’t fully settled, but the general level of sales
enquiries remains strong. Our FY23 and FY24 estimates are broadly
unchanged, with the exception of an increased interest charge given the
current interest rate environment."
"SDI is benefitting from its niche positions and product diversity. Another
strong first half highlights management’s ability to execute its ‘buy and
build’ strategy and deliver outstanding results, despite residual Covid
disruption and inflationary supply chain pressures. SDI is well-positioned to
continue to grow underlying organic revenue and profitability, with a strong
acquisition pipeline underpinned by cash generation and financial strength."
"Summary and outlook
SDI remains focused on smaller niche businesses operating with a high degree of autonomy, allowing a fast response, with good opportunities to consolidate the highly fragmented markets that the group targets. Results with acquisitions so far have been exceptional, delivering strong financial returns and operational synergies. The specialist nature of technical, scientific, and medical and life science market segments offers a significant opportunity for increased shareholder value.
We also haven’t assumed a contribution from potential new acquisitions, which offers upside to our estimates.
The group is in a strong position financially, with good operational cash flows and a solid order book. Management continues to seek targeted acquisitions funded by cash flows from existing businesses and its £6m undrawn facilities, and given strong cashflow we forecast net debt to be broadly neutral by the end of FY24. We believe that SDI is in a strong position to continue to deliver its successful ‘buy and build’ business model."